Premium
Topical recombinant human acidic fibroblast growth factor: An effective therapeutic agent for facemask wearing‐induced pressure sores
Author(s) -
Luo Pan,
Liu Dong,
Li Juan
Publication year - 2020
Publication title -
dermatologic therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.595
H-Index - 68
eISSN - 1529-8019
pISSN - 1396-0296
DOI - 10.1111/dth.13745
Subject(s) - medicine , pressure sores , covid-19 , nose , wound healing , surgery , intensive care medicine , anesthesia , disease , infectious disease (medical specialty)
Protecting health care workers is crucial during coronavirus disease 2019 pandemic and facemask wearing is considered an effective measure to prevent severe acute respiratory syndrome coronavirus 2 infection. However, long‐time use of a facemask can cause pressure sores on the ears and nose bridge and increase the risk of infection. The topical recombinant human acidic fibroblast growth factor (rh‐aFGF) was used to cure pressure sores for health care workers at Zhongfaxincheng campus of Tongji Hospital. The results from a small sample size survey conducted in Zhongfaxincheng campuses of Tongji Hospital showed that treatment with topical rh‐aFGF could significantly inhibit the progression of pressure sores and accelerate the wound healing with no apparent ill‐effects. Therefore, we propose that topical rh‐aFGF is an effective therapeutic agent for facemask wearing‐induced pressure sores and worth of popularizing and applying.